All Episodes

92 - Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma (ENDURANCE, N Engl J Med 2026)

91 - Bridging Therapy Response and Type as Determinants of Cilta-cel Outcomes in Relapsed-Refractory Multiple Myeloma (Blood Cancer J 2026)

90 - Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma (SUNMO, J Clin Oncol 2025)

89 - Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia (PARADIGM, N Engl J Med 2026)

88 - Haploidentical Bone Marrow Transplantation for Sickle Cell Disease (BMT CTN 1507, NEJM Evidence 2025)

87 - Tafasitamab + lenalidomide + R-CHOP vs R-CHOP in high-risk DLBCL (frontMIND, Lancet 2026)

86 - Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

85 - Non-Myeloablative versus Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged ≥65: A Study from the ALWP of EBMT

84 - High-Dose Busulfan-Melphalan vs. Melphalan and Reinforced VRD in Newly Diagnosed Multiple Myeloma. A Phase III GEM Trial

83 - Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia

82 - All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia

81 - Carfilzomib, lenalidomide, dexamethasone vs lenalidomide after autologous HSCT in multiple myeloma (ATLAS): phase 3 trial

80 - Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

79 - Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

78 - Three-Hour Infusion of Methotrexate at 3 g/m² With or Without Intrathecal Chemotherapy Reduces CNS Relapses and Improves Survival in Large B-Cell Lymphomas at Increased CNS Risk

77 - Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

76 - Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

75 - Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

74 - Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

73 - Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

72 - Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

71 - Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

70 - Intermediate-Dose Cytarabine as Postinduction AML Therapy

69 - Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation

61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

59 - Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study

57 - A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults

56 - Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

55 - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

54 - Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

53 - Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

52 - Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

51 - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

50 - Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

48 - Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

47 - Dar­a­tum­umab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

46 - Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

45 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

44 - Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML

43 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)

41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors

38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

34 - Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

33 - Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

32 - The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial

31 - Remission induction vs immediate allogeneic HSCT for patients with relapsed or poor responsive AML (ASAP): a randomised, open-label, phase 3, non-inferiority trial

30 - Ibrutinib combined with immunochemotherapy with or without ASCT vs immunochemotherapy and ASCT in previously untreated patients with mantle cell lymphoma (TRIANGLE)

29 - Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT

28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial

27 - Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

26 - Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

25 - PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors

24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

23 - Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up

22 - Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention

21 - Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

20 - Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

19 - Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML

15 - Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation

14 - BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial

13 - R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma

12 - PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation

11 - Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER)

10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

09 - Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis

08 - Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL

07 - Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients

06 - Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

05 - Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD AML: long-term follow-up of an open-label, multicentre, randomised, phase 3

04 - Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3

03 - Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia